D

Dongkook Pharmaceutical Co Ltd
KOSDAQ:086450

Watchlist Manager
Dongkook Pharmaceutical Co Ltd
KOSDAQ:086450
Watchlist
Price: 16 710 KRW 2.26%
Market Cap: 734.6B KRW
Have any thoughts about
Dongkook Pharmaceutical Co Ltd?
Write Note
Dongkook Pharmaceutical Co Ltd
/
Balance Sheet
/
Note Receivable

Dongkook Pharmaceutical Co Ltd
Note Receivable

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
|

Dongkook Pharmaceutical Co Ltd
Note Receivable Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Note Receivable CAGR 3Y CAGR 5Y CAGR 10Y
D
Dongkook Pharmaceutical Co Ltd
KOSDAQ:086450
Note Receivable
-₩25.3m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Yuhan Corp
KRX:000100
Note Receivable
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
SK Biopharmaceuticals Co Ltd
KRX:326030
Note Receivable
₩84.8m
CAGR 3-Years
N/A
CAGR 5-Years
16%
CAGR 10-Years
N/A
Hanmi Pharm Co Ltd
KRX:128940
Note Receivable
₩17.3B
CAGR 3-Years
48%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
S
Sam Chun Dang Pharm Co Ltd
KOSDAQ:000250
Note Receivable
₩6.7B
CAGR 3-Years
N/A
CAGR 5-Years
46%
CAGR 10-Years
N/A
C
Celltrion Pharm Inc
KOSDAQ:068760
Note Receivable
₩130.7m
CAGR 3-Years
-76%
CAGR 5-Years
N/A
CAGR 10-Years
-26%
No Stocks Found

Dongkook Pharmaceutical Co Ltd
Glance View

Market Cap
734.7B KRW
Industry
Pharmaceuticals

DongKook Pharmaceutical Co., Ltd. engages in the manufacture and sale of pharmaceuticals. The company is headquartered in Seoul, Seoul. The company went IPO on 2007-05-29. The firm develops and provides remedies for oral troubles, skin troubles and gynecology diseases, contrast mediums, anesthetics, anticancer medicines and circulatory system agents. The company also provides other pharmaceuticals, such as remedies for arthritis and pancreatitis, antiphlogistic, anodynes, antibiotics and vitamins, as well as raw materials for pharmaceuticals. In addition, it is engaged in the rental business. The firm distributes its products within domestic market and to overseas markets, such as Japan, Germany, India, Brazil and Mexico, among others.

Intrinsic Value
19 388.02 KRW
Undervaluation 14%
Intrinsic Value
Price
D
What is Intrinsic Value?

See Also

What is Dongkook Pharmaceutical Co Ltd's Note Receivable?
Note Receivable
-25.3m KRW

Based on the financial report for Sep 30, 2024, Dongkook Pharmaceutical Co Ltd's Note Receivable amounts to -25.3m KRW.

Back to Top
ALPHA SPREAD
Follow us
Join more than 211,000+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.